Upcoming Stock Splits May 12 to May 16: Cyclacel Pharmaceuticals, Solidion Technology, Alzamend Neuro, Cardio Diagnostics Holdings, Moolec Science, TransCode Therapeutics, Peoples.

Upcoming stock splits for the week of May 12 to May 16 include Cyclacel Pharmaceuticals (CYCC), Solidion Technology (STI), Alzamend Neuro (ALZN), Cardio Diagnostics Holdings (CDIO), Moolec Science (MLEC), TransCode Therapeutics (RNAZ), and Peoples (PPLL). These companies are carrying out reverse stock splits to regain compliance with Nasdaq's minimum bid price requirement and maintain listing compliance.

Cyclacel Pharmaceuticals (CYCC) is among several companies scheduled to undergo reverse stock splits from May 12 to May 16. This move is primarily aimed at regaining compliance with Nasdaq's minimum bid price requirement and maintaining listing compliance. Cyclacel, Solidion Technology (STI), Alzamend Neuro (ALZN), Cardio Diagnostics Holdings (CDIO), Moolec Science (MLEC), TransCode Therapeutics (RNAZ), and Peoples (PPLL) are all expected to implement reverse stock splits during this period.

Cyclacel Pharmaceuticals, a biopharmaceutical company focused on innovative cancer treatments, announced a 1-for-16 reverse stock split effective May 12, 2025 [1]. The split will reduce the number of shares from approximately 356 million to about 22 million, while the overall percentage ownership of shareholders will remain unchanged. The reverse stock split is expected to help increase the stock price and improve market perception. The company's board of directors and stockholders have approved the split, indicating strong support from leadership and investors.

The reverse stock split for Cyclacel Pharmaceuticals is part of a broader trend among companies aiming to meet Nasdaq's minimum bid price requirements. Reverse stock splits can help companies avoid delisting by reducing the number of shares and increasing the price per share. However, they may also signal to investors that the company's stock price is struggling, potentially indicating underlying financial or operational issues.

Institutional investors have shown interest in Cyclacel Pharmaceuticals, with several hedge funds adding shares to their portfolios in recent quarters [1]. This interest could be driven by the company's pipeline of innovative drug candidates, including plogosertib, a PLK1 inhibitor being evaluated in patients with both solid tumors and hematological malignancies.

While the reverse stock split may simplify the share structure and make the stock more appealing to institutional investors, it is essential for investors to consider the broader implications. The press release does not provide concrete updates or assurances about the progress of drug development or financial health, which may raise concerns among investors regarding the company's future prospects.

References:
[1] https://www.nasdaq.com/articles/cyclacel-pharmaceuticals-announces-1-16-reverse-stock-split-effective-may-12-2025